pharmaceutical investing Auris Medical Closes Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD
pharmaceutical investing Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
